Developing discriminatory drug dissolution tests and profiles: Some thoughts for consideration on the concept and its interpretation

Dissolution Technologies

Volumn 13, Issue 4, 2006, Pages 18-23

  Qureshi, Saeed A ^a  

^a Health Canada and World Health Organization Collaborating Center for Standardization and Evaluation of Biologicals   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE;

ARTICLE; BIOEQUIVALENCE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG RELEASE; DRUG SOLUBILITY; GASTROINTESTINAL TRACT; QUALITY CONTROL;

EID: 84962081960     PISSN: 1521298X     EISSN: None     Source Type: Journal    
DOI: 10.14227/DT130406P18     Document Type: Article

References (27)

1. USP General Chapter on Dissolution <711>. United States Pharmacopeia and National Formulary; United States Pharmacopeial Convention, Inc.: Rockville, MD, 2005; pp 2412-2414.
2. Levy, G. Effect of dissolution rate on absorption, metabolism, and pharmacologic activity of drugs. J. Mond. Pharm. 1967, 3, 237-254.
3. Wagner, J. G. Biopharmaceutics and Relevant Pharmacokinetics; Drug Intelligence Publications: Hamilton, IL, 1971; Chapter 10.
4. Abdou, H. M. Dissolution, Bioavailability, and Bioequivalence; Mack Publishing Company: Easton, PA, 1989; p 6.
5. Dissolution Testing of Immediate Release Solid Oral Dosage Forms; Guidance for Industry; U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), U. S. Government Printing Office: Washington, DC, 1997. http: //www. fda. gov/cder/guidance/ 1713bp1. pdf
6. Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations; Guidance for Industry; U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), U. S. Government Printing Office: Washington, DC, 1997. http: //www. fda. gov/cder/guidance/1306fnl. pdf.
7. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Forms Containing Certain Active Moieties/Active Ingredients Based on Biopharmaceutics Classification System; Guidance for Industry; U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), U. S. Government Printing Office: Washington, DC, 2000. http: //www. fda. gov/cder/guidance/3618fnl. pdf.
8. Moore, J. J.; Flanner, H. H. Mathematical comparison of curves with an emphasis on in vitro dissolution profiles. Pharm. Tech. 1996, 20, 64-74.
9. Shah, V. P., Tsong, L., Sathe, P., Williams, R. L. Dissolution Profile Comparison Using Similarity Factor, f2. Dissolution Technol. 1999, 6 (3), 21.
10. USP General Chapter <1092> the Dissolution Procedure: Development and Validation. Pharm. Forum 2004, 30, 351-363.
11. USP General Chapter on In Vitro and In Vivo Evaluation of Dosage Forms <1088>. United States Pharmacopeia and National Formulary; United States Pharmacopeial Convention, Inc.: Rockville, MD, 2005, pp 2636-2641.
12. McNamara, P. J.; Foster, T. S.; Digenis, G. A.; Patel, R. B.; Craig, W. A.; Welling, P. G.; Rapaka, R. S.; Prasad, V. K.; Shah, V. P. Influence of tablet dissolution on furosemide bioavailability: a bioequivalence study. Pharm. Res. 1987, 4, 150-153.
13. Meyer, M. C.; Straughn, A. B.; Mhatre, R. M.; Shah, V. P.; Williams, R. L.; Lesko, L. J. Lack of in vivo/in vitro correlations for 50 mg and 250 mg primidone tablets. Pharm Res. 1998, 15, 1085-1089.
14. Lake, O. A.; Olling, M.; Barends, D. M. In vitro/in vivo correlations of dissolution data of carbamazepine immediate release tablets with pharmacokinetic data obtained in health volunteers. Eur. J. Pharm. Biopharm. 1999, 48, 13-19.
15. Leeson, L. J. In vitro/in vivo correlations. Drug Inf. J. 1995, 29, 903-915.
16. Abrahamsson, B.; Johansson, D.; Torstensson, A.; Wingstrand, K. Evaluation of solubilizers in the drug release testing of hydrophilic matrix extendedrelease tablets of felodipine. Pharm. Res. 1994, 8, 1093-1097.
17. Cox, D. C.; Wells, C. E.; Furman, W. B.; Savage, T. S.; King, A. C. Systematic Error Associated with Apparatus 2 of the USP Dissolution Test II: Effects of Deviations in Vessel Curvature From That of a Sphere. J. Pharm. Sciences. 1982, 71, 395- 399.
18. Kukura, J.; Baxter, J. L.; Muzzio, F. J. Shear Distribution and Variability in the USP Apparatus 2 under Turbulent Conditions. Int. J. Pharm. 2004, 26, 9-17.
19. McCarthy, L. G.; Kosiol, C.; Healy, A. M.; Bradley, G.; Sexton, J. C.; Corrigan, O. I. Simulating the Hydrodynamic Conditions in the United States Pharmacopeia Paddle Dissolution Apparatus. AAPS PharmSciTech 2003, 4, 172-187.
20. Morihara, M.; Aoyagi, N.; Kaniwa, N.; Katori, N.; Kojim, S. Hydrodynamic Flows Around Tablets in Different Pharmacopeial Dissolution Tests. Drug Develop. Ind. Pharm. 2002, 28, 655-662.
21. Qureshi, S. A.; Shabnam, J. Cause of high variability in drug dissolution testing and its impact on setting tolerance. Eur. J. Pharm. Sci. 2001, 12, 271-276.
22. Qureshi, S. A.; Shabnam, J. Application of a new device (spindle) for improved characterization of drug release (dissolution) of pharmaceutical products. Eur. J. Pharm. Sci. 2003, 19, 291-297.
23. Qureshi, S. A. A new crescent-shaped spindle for drug dissolution testing-but why a new spindle? Dissolution Technol. 2004, 11 (4) 13-18.
24. Qureshi, S. A. Choice of rotation speed (rpm) for biorelevant drug dissolution testing using a Crescentshape spindle. Eur. J. Pharm. Sci. 2004, 23, 271-275.
25. Leeson, L. J.; Mayersohn, M. Letter to the Editor. Dissolution Technol. 2005, 12, 24-33.
26. Carbamazepine Tablets Monograph. United States Pharmacopeia and National Formulary; United States Pharmacopeial Convention, Inc.: Rockville, MD, 2005; pp 342-343.
27. Carbamazepine Extended-Release Tablets Monograph. United States Pharmacopeia and National Formulary; United States Pharmacopeial Convention, Inc.: Rockville, MD, 2005; pp 343-344.